Ultragenyx price target raised to $121 from $109 at Canaccord

Canaccord raised the firm’s price target on Ultragenyx (RARE) to $121 from $109 and keeps a Buy rating on the shares. The firm said they once again delivered a top-line beat which was driven by global Crysvita and Evkeeza demand.